FORM 8.1(a) & (b) (Opening Position Disclosure)
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: Nov 05 20250mins
Disclosure of Offeror: Alkermes plc has disclosed its position as the offeror in relation to Avadel Pharmaceuticals plc under the Irish Takeover Panel rules, with the latest position held as of November 3, 2025.
Interests and Positions: The disclosure includes interests and short positions, with no additional interests reported beyond those of J.P. Morgan, which holds a minor percentage of shares.
No Inducements or Agreements: Alkermes plc reported no indemnity or option arrangements that could influence dealings in relevant securities, indicating a straightforward disclosure.
Contact Information: The disclosure was made public on November 5, 2025, with Sandy Coombs as the contact person for further inquiries.
ALKS.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ALKS
Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 44.50 USD with a low forecast of 34.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 29.300
Low
34.00
Averages
44.50
High
58.00
Current: 29.300
Low
34.00
Averages
44.50
High
58.00
Jefferies
Hold
downgrade
$23
2025-11-26
Reason
Jefferies
Price Target
$23
2025-11-26
downgrade
Hold
Reason
Jefferies lowered the firm's price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $23 and keeps a Hold rating on the shares as the firm expects the deal to be acquired by Alkermes (ALKS) to close in Q1 of 2026 after Lundbeck decided not to raise its November 14 offer. The firm now thinks the chances of a competing bid are unlikely and lowered its target to reflect Alkermes' November 18 offer to acquire Avadel for $22.50 per share, including $21 upfront and a $1.50 per share CVR.
Guggenheim
Buy
upgrade
$28 -> $43
2025-11-18
Reason
Guggenheim
Price Target
$28 -> $43
2025-11-18
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Centessa (CNTA) to $43 from $28 and keeps a Buy rating on the shares following the "promising" preliminary readout from the ORX750 CRYSTAL-1 Ph2a study as well as the "relatively underwhelming" results from alixorexton in NT2 that were reported by Alkermes (ALKS).
Truist
Buy
maintain
$50 -> $55
2025-11-17
Reason
Truist
Price Target
$50 -> $55
2025-11-17
maintain
Buy
Reason
Truist raised the firm's price target on Alkermes (ALKS) to $55 from $50 and keeps a Buy rating on the shares. Positive Vibrance-2 results materially de-risk the alixorexton program, supporting a higher probability of success and stronger estimates, the analyst tells investors in a research note. Cross-trial comparisons show alixorexton outperforming oveporexton in NT2, and the added split-dosing regimen in Phase 3 could further enhance efficacy, with Takeda (TAK) management viewing the program as credible competitive pressure.
Deutsche Bank
David Hoang
Buy
downgrade
$55 -> $45
2025-11-13
Reason
Deutsche Bank
David Hoang
Price Target
$55 -> $45
2025-11-13
downgrade
Buy
Reason
Deutsche Bank analyst David Hoang lowered the firm's price target on Alkermes to $45 from $55 and keeps a Buy rating on the shares. The company announced positive topline data from its Phase 2 VIBRANCE-2 trial of alixorexton in narcolepsy type 2, but results came in below the high expectations needed for the drug to be a "clear best-in-class therapy," the analyst tells investors in a research note. The firm believes the shares dropped yesterday on a perceived less competitive commercial profile for alixorexton versus peers.
See All Ratings
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the purpose of Alkermes acquiring Avadel under Irish law?
How does the shareholder vote ensure transparency in the acquisition process?
How might Alkermes' market position change after acquiring Avadel?
What are the potential outcomes of the January 12 shareholder vote?